HER2: a never ending story
- PMID: 34252373
- DOI: 10.1016/S1470-2045(21)00349-1
HER2: a never ending story
Conflict of interest statement
MVD declares personal fees from Eli Lilly (invited speaker, advisory board), Seagen (advisory board), Novartis (advisory board), and Pfizer (invited speaker); an institutional research grant from Istituto Oncologico Veneto IOV-IRCCS, the Italian Ministry of Health, and the University of Padova, Italy, all outside the submitted work. FM declares no competing interests.
Comment on
-
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.Lancet Oncol. 2021 Aug;22(8):1151-1161. doi: 10.1016/S1470-2045(21)00301-6. Epub 2021 Jul 9. Lancet Oncol. 2021. PMID: 34252375
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous